Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
10 December, 2018 12:56 IST
Strides Shasun receives USFDA approval for Efavirenz tablets
Source: IRIS | 14 Mar, 2018, 09.44AM
Comments  |  Post Comment

Strides Shasun today announced that it's wholly owned subsidiary Strides Pharma Global has received approval for Efavirenz Tablets USP, 600 mg from the United States Food & Drug Administration (US FDA). Efavirenz Tablet is generic version of Sustiva Tablets of Bristol-Myers Squibb Company.

According to IQVIA data, the US market for Efavirenz Tablets USP, 600 mg is approximately USD 115 Million and Strides is only the second generic company to get the approval for the product under the para IV route. The product will be manufactured at the company's Oral dosage facility at Bangalore and will be marketed by Strides Pharma Inc. in the US Market. Strides is launching the product immediately.

The company has 74 cumulative ANDA filings with USFDA of which 44 ANDAs have been approved as of date and 30 are pending approval.

Shares of the company gained Rs 7.55, or 1.12%, to trade at  Rs 683.30.  The total volume of shares traded  was  2,073 at the BSE (9.31 a.m., Wednesday).



Strides Pharma Science Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Company Update
HCL Tech to acquire select IBM Software products for USD 1.8 bn - 07-Dec-2018 10:08
Wipro, Alfresco expand pact to offer digital transformation capabilities - 07-Dec-2018 09:59
Indian Hume Pipe Co receives contract worth Rs 2.04 bn - 06-Dec-2018 09:50
Infosys inaugurates technology and innovation hub in Hartford - 06-Dec-2018 09:46
USFDA completes inspection of Lupin's Mandideep location - 05-Dec-2018 15:31
NTPC wins 85MW solar projects in UPNEDA's solar tender - 05-Dec-2018 15:03
Alembic Pharma gets USFDA nod for Candesartan Cilexetil tablets - 05-Dec-2018 13:05
Kridhan Infra's associate Co bags orders worth Rs 1.05 bn - 05-Dec-2018 10:06
Lupin launches generic Silodosin capsules in United States - 05-Dec-2018 09:54
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer